ASR Vermogensbeheer N.V. Has $30.01 Million Stock Position in IQVIA Holdings Inc. $IQV

ASR Vermogensbeheer N.V. lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 158,010 shares of the medical research company’s stock after selling 13,585 shares during the quarter. ASR Vermogensbeheer N.V.’s holdings in IQVIA were worth $30,012,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Versant Capital Management Inc lifted its position in IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. Private Trust Co. NA increased its holdings in IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares during the period. E Fund Management Co. Ltd. raised its stake in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after buying an additional 74 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after acquiring an additional 78 shares during the period. Finally, Hemington Wealth Management boosted its position in shares of IQVIA by 43.4% during the 3rd quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 79 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 1.3%

Shares of NYSE IQV opened at $238.03 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a market cap of $40.54 billion, a price-to-earnings ratio of 32.65, a price-to-earnings-growth ratio of 2.45 and a beta of 1.36. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The firm’s 50-day simple moving average is $227.30 and its 200 day simple moving average is $203.05.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. TD Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating and increased their price target for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Barclays set a $230.00 target price on IQVIA in a report on Monday, December 15th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. BMO Capital Markets began coverage on IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target on the stock. Finally, Evercore ISI lifted their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.